Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel + anlotinib + camrelizumab versus albumin-bound paclitaxel + platinum as first-line therapy for advanced squamous NSCLC
ChiCTR2100046969Phase 3Not yet recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paclitaxel, anlotinib and camrelizumab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Hubei Cancer Hospital. Primary endpoint: Progression-free survival time. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
paclitaxelanlotinibcamrelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2100046969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046969.